CClinicalTrials.gg
Approved for marketingNCT01858103Updated Apr 2, 2014

BMN 110 US Expanded Access Program

An expanded access record providing BMN 110 in Mucopolysaccharidosis IVA, Morquio A Syndrome and MPS IVA, sponsored by BioMarin Pharmaceutical. Approved for marketing at 25 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-04-02.

Sponsored by BioMarin Pharmaceutical · Expanded access

Study type
Expanded access
Sex
All
01

Study summary

The Expanded Access Program (EAP) is an open-label, multicenter program to:

  1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available
  2. Collect additional information on the safety and tolerability of BMN 110 administration in patients with MPS IVA

Patients enrolled in the EAP will receive 2.0 mg/kg intravenous infusions of BMN 110 every week during the program.

02

Conditions studied

  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

Keywords

  • Mucopolysaccharidosis IVA Type A
  • MPS IVA Type A
  • Mucopolysaccharidosis IVA
  • MPS IVA
  • Morquio A Syndrome
  • Lysosomal Storage Disorder
  • LSD
  • N-acetylgalactosamine-6-sulfatase
  • N-acetylgalactosamine-6-sulfate
03

In context

Mucopolysaccharidoses

145 studies on the registry are indexed under Mucopolysaccharidoses; 11 are open to participants now.

Browse Mucopolysaccharidoses studies →

Lead sponsor

BioMarin Pharmaceutical is the lead sponsor of 110 studies on the registry; 13 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Inclusion criteria

  • Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine-6-sulfatase (GALNS) enzymatic test (GALNS activity in affected range, beta-galactosidase and a second lysosomal sulfatase activity within normal range) or molecular diagnostic test (two mutations in GALNS identified that have previously been associated with an enzyme defect).
  • Willing and able to provide written, signed informed consent, or in the case of patients under the age of 18, provide written assent (as required by the IRB) and written informed consent by a legally authorized representative after the nature of the program has been explained, and prior to any program assessments or evaluations.
  • Sexually active patients must be willing to use an acceptable method of contraception while participating in the program.
  • Females of childbearing potential must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests during the program.
  • Willing and able to comply with all program procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the program. Patients who become pregnant during the program will be discontinued from the program.
  • Currently enrolled in an ongoing clinical study of BMN 110.
  • Discontinued from a BMN 110 clinical study secondary to a safety-related event.
  • Use of any investigational product (other than BMN 110 in a clinical study) or investigational medical device within 30 days prior to Baseline, or requirement for any investigational agent prior to completion of all scheduled program assessments.
  • Not a current US resident or expecting to have travel plans outside the US during the planned period of participation in the Expanded Access Program (EAP) that may interfere with dosing regimen, scheduled program visits and safety monitoring.
  • Any condition that, in the view of the Investigator or sponsor, places the patient at high risk of poor treatment compliance or of not completing the EAP.
05

Access details

Study type
Expanded access

Available treatment

  • DrugBMN 110
06

Where to request access

25 sites
  • Birmingham, Alabama 35294, United States
  • Little Rock, Arkansas 72202, United States
  • Oakland, California 94609, United States
  • Orange, California, United States
  • Aurora, Colorado, United States
  • Washington, District of Columbia 20010, United States
  • Hollywood, Florida 33021, United States
  • Miami, Florida, United States
  • Atlanta, Georgia 30033, United States
  • Chicago, Illinois 60611, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Minneapolis, Minnesota 55404, United States
  • Paterson, New Jersey, United States
  • Manhasset, New York 11030, United States
  • New York, New York, United States
  • Portland, Oregon 97239, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah 84113, United States
  • Seattle, Washington, United States
  • Tacoma, Washington 98405, United States
  • Santurce, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01858103
Lead sponsor
BioMarin Pharmaceutical
Responsible party
Sponsor
First posted
May 21, 2013
Last update
Apr 2, 2014
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion